Aldeyra Therapeutics
Case Overview
59 Days Left to Seek Lead Plaintiff
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 05/29/2026 |
| Status: | Status: Investigating |
| Company Name: | Company Name: Aldeyra Therapeutics |
| Court: | Court: District of Massachusetts |
| Case Number: | Case Number: 1:26cv11510 |
| Class Period: | Class Period: 11/03/2023 - 03/16/2026 |
| Ticker: | Ticker: ALDX |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Aldeyra Therapeutics (“Aldeyra” or the “Company”) (NASDAQ:ALDX) securities during the period of November 3, 2023 through March 16, 2026, inclusive (“the Class Period”).
The lawsuit alleges that Aldeyra failed to disclose that (1) the results of the reproxalap (an Aldeyra drug candidate) clinical trials were inconsistent; and (2) the inconsistency of the results rendered any purported positive findings from these trials unreliable and not meaningful.
On March 17, 2026, the Company filed with the SEC a current report on Form 8-K, announcing receipt of a Complete Response Letter from the FDA, stating that there is “a lack of substantial evidence consisting of adequate and well-controlled investigations … that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling” and that “the application has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease.” The Complete Response Letter also stated that the “inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings” and that “the totality of evidence from the completed clinical trials does not support the effectiveness of the product.” On this news, the price of Aldeyra shares declined by $2.99 per share, or approximately 71%, from $4.23 per share on March 16, 2026 to close at $1.24 on march 17, 2026.
The lawsuit alleges that Aldeyra failed to disclose that (1) the results of the reproxalap (an Aldeyra drug candidate) clinical trials were inconsistent; and (2) the inconsistency of the results rendered any purported positive findings from these trials unreliable and not meaningful.
On March 17, 2026, the Company filed with the SEC a current report on Form 8-K, announcing receipt of a Complete Response Letter from the FDA, stating that there is “a lack of substantial evidence consisting of adequate and well-controlled investigations … that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling” and that “the application has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease.” The Complete Response Letter also stated that the “inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings” and that “the totality of evidence from the completed clinical trials does not support the effectiveness of the product.” On this news, the price of Aldeyra shares declined by $2.99 per share, or approximately 71%, from $4.23 per share on March 16, 2026 to close at $1.24 on march 17, 2026.